风湿性关节炎与肺加速性风湿性结节治疗巴里西提尼:基于病例的综述
Haijun Liu1, Qianhua Li2, Kangxia Long1
1Department of Rheumatology, Panyu Central Hospital, Guangzhou, China.
Clinical rheumatology
|September 22, 2023
概括
肺部加速性类风湿性结节 (RNA) 在类风湿性关节炎 (RA) 中很少见. 这项案例研究表明,Janus激酶抑制剂巴里西丁尼 (baricitinib) 有效地减少了肺RNA大小,这表明了新的治疗选择.
科学领域:
- 类风湿病学 类风湿病学
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺加速性类风湿结节 (RNA) 是类风湿性关节炎 (RA) 的不常见表现.
- 传统的治疗包括皮质类固醇,但需要新的治疗策略.
- 特定疾病修饰性抗风湿药物 (DMARDs) 在RNA发育中的作用正在研究中.
研究的目的:
- 报告一个独特的肺性RNA病例,该病例成功地用Janus激酶抑制剂巴里西提尼布治疗.
- 审查有关肺性RNA及其管理的现有文献.
- 评估Janus激酶抑制剂作为RNA治疗的潜力.
主要方法:
- 一个46岁的女性RA患者的病例报告,新诊断的肺性RNA.
- 诊断程序包括胸部计算机断层扫描 (CT) 和胸腔镜活检.
- 自1986年以来发表的关于肺性RNA的45篇文章的文献评论.
- 治疗包括巴里丁,Janus激酶抑制剂 (JAK抑制剂) 和合成修饰疾病的抗风湿药物 (DMARD).
主要成果:
- 胸部CT显示了多个双边肺结节,通过活检确认为类风湿结节.
- 用巴里西提尼布治疗导致结核大小显著减少.
- 文献审查发现了13例肺性RNA病例报告,通常与呼吸系统症状和特定的DMARD相关.
- CT检测结果通常包括多个固体结节或地面玻璃不透明度,有时有空洞.
结论:
- 巴里西替尼 (Baricitinib) 是一种 Janus 激酶抑制剂,在这种 RA 患者的肺 ARN 尺寸降低方面表现出有效性.
- 简氏激酶抑制剂代表了管理肺性RNA的有前途的治疗选择.
- 需要进一步的研究来证实JAK抑制剂在RNA治疗中的作用,并阐明潜在的机制.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Rheumatic Heart Disease III: Medical Management
11
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
11
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
Pulmonary Tuberculosis II
256
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
256
Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K


